Key Insights

Highlights

Success Rate

84% trial completion

Published Results

92 trials with published results (20%)

Research Maturity

262 completed trials (56% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

10.5%

49 terminated out of 465 trials

Success Rate

84.2%

-2.3% vs benchmark

Late-Stage Pipeline

8%

39 trials in Phase 3/4

Results Transparency

35%

92 of 262 completed with results

Key Signals

92 with results84% success49 terminated

Data Visualizations

Phase Distribution

375Total
Not Applicable (72)
Early P 1 (6)
P 1 (96)
P 2 (162)
P 3 (28)
P 4 (11)

Trial Status

Completed262
Recruiting61
Terminated49
Unknown46
Active Not Recruiting24
Withdrawn14

Trial Success Rate

84.2%

Benchmark: 86.5%

Based on 262 completed trials

Clinical Trials (465)

Showing 20 of 20 trials
NCT07646847Not ApplicableRecruitingPrimary

A Study of a Side Effects and Resource Navigation Program for People With Cancer

NCT00001238RecruitingPrimary

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

NCT02974738Phase 1Active Not Recruiting

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

NCT00050752Recruiting

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

NCT06955910Completed

Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies.

NCT01217931Phase 2Active Not RecruitingPrimary

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

NCT06580002Phase 2Recruiting

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

NCT03345563Not ApplicableCompleted

Project HERO: Health Empowerment & Recovery Outcomes

NCT04000880Not ApplicableCompleted

Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health

NCT00403169Phase 2CompletedPrimary

Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer

NCT00026884Recruiting

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT02964078Phase 2CompletedPrimary

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

NCT07059884Not ApplicableRecruiting

Distance-Based Exercise to Preserve Function and Prevent Disability

NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT05520099Active Not Recruiting

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)

NCT07327489Recruiting

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

NCT07672860Phase 2RecruitingPrimary

Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors

NCT03293563RecruitingPrimary

UroCCR Database: French Research Network for Kidney Cancer -UroCCR

NCT05820087Not ApplicableActive Not Recruiting

The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)

NCT05708950Phase 1Completed

A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Scroll to load more

Research Network

Activity Timeline